• ورود به سامانه
      مشاهده مورد 
      •   صفحهٔ اصلی
      • نشریات انگلیسی
      • International Journal of Health Policy and Management
      • Volume 7, Issue 12
      • مشاهده مورد
      •   صفحهٔ اصلی
      • نشریات انگلیسی
      • International Journal of Health Policy and Management
      • Volume 7, Issue 12
      • مشاهده مورد
      JavaScript is disabled for your browser. Some features of this site may not work without it.

      Impact of “Sambhav” Program (Financial Assistance and Counselor Services) on Hepatitis C Pegylated Interferon Alpha Treatment Initiation in India

      (ندگان)پدیدآور
      Sood, AjitMidha, VandanaHalli, Shivalingappa S.Narang, VikramMahajan, RamitMehta, VarunKaur, KirandeepSurlikar, VijayKanchi, SubodhSingh, Dharmatma
      Thumbnail
      دریافت مدرک مشاهده
      FullText
      اندازه فایل: 
      938.1کیلوبایت
      نوع فايل (MIME): 
      PDF
      نوع مدرک
      Text
      Original Article
      زبان مدرک
      English
      نمایش کامل رکورد
      چکیده
      Background Financial constraints, social taboos and beliefs in alternative medicine are common reasons for delaying or not considering treatment for hepatitis C in India. The present study was planned to analyze the impact of non-banking interest free loan facility in patients affected with hepatitis C virus (HCV) in North India.   Methods This one year observational, retrospective study was conducted in Department of Gastroenterology (January 2012-December 2013), Dayanand Medical College and Hospital Ludhiana, to evaluate the impact of program titled “Sambhav" (which provided non-banking financial assistance and counselor services) on treatment initiation and therapeutic compliance in HCV patients. Data of fully evaluated patients with chronic hepatitis, and/or cirrhosis due to HCV infection who were treated with Peginterferon alfa and ribavirin (RBV) combination during this duration (2012-2013) was collected from patient medical records and analyzed. In the year 2012, eligible patients who were offered antiviral treatment paid for treatment themselves, while in 2013, ‘Sambhav' program was launched and this provided interest free financing by non-banking financial company (NBFC) for the treatment of HCV in addition to free counselor services for disease management. The treatment initiation and compliance rates were compared between the patients (n = 585) enrolled in 2013 who were offered ‘Sambhav' assistance and those enrolled in 2012 (n = 628) when ‘Sambhav' was not available.   Results Introduction of Sambhav program improved the rates of treatment initiation (59% in 2013 vs. 51% in 2012, P = .004). Of the 585 eligible patients offered ‘Sambhav' assistance in 2013, 233 patients (39.8%) applied but 106/233 (45.4%) received assistance. Antiviral therapy was started in 93/106 (87.7%) of these patients, while only 52 (42.5%) of 127 patients whose applications were rejected underwent treatment. Compliance to antiviral therapy also improved with the introduction of ‘Sambhav' program (87.7% vs. 74.1%, P = .001).   Conclusion ‘Sambhav' program had significant impact on the initiation of antiviral therapy by overcoming the financial hurdles. The free counselor services helped to mitigate social taboos and imparted adequate awareness about the disease to the patients. Initiatives like ‘Sambhav' can be utilized for improving healthcare services in developing countries, especially for chronic diseases.
      کلید واژگان
      Sambhav Program
      Hepatitis C
      Pegylated Interferon Gamma
      Treatment Access
      India
      Health Insurance

      شماره نشریه
      12
      تاریخ نشر
      2018-12-01
      1397-09-10
      ناشر
      Kerman University of Medical Sciences
      سازمان پدید آورنده
      Department of Gastroentrology, Dayanand Medical College and Hospital (DMCH), Ludhiana, India
      Department of Internal Medicine, Dayanand Medical College and Hospital (DMCH), Ludhiana, India
      University of Manitoba, Winnipeg, MN, Canada
      Department of Pathology, Dayanand Medical College & Hospital (DMCH), Ludhiana, India
      Department of Gastroentrology, Dayanand Medical College and Hospital (DMCH), Ludhiana, India
      Department of Gastroentrology, Dayanand Medical College and Hospital (DMCH), Ludhiana, India
      Department of Pharmacology, Dayanand Medical College and Hospital, Ludhiana, India
      MSD Pharmaceutical Pvt Ltd, Bandra, India
      MSD Pharmaceutical Pvt Ltd, Bandra, India
      Department of Gastroentrology, Dayanand Medical College and Hospital (DMCH), Ludhiana, India

      شاپا
      2322-5939
      URI
      https://dx.doi.org/10.15171/ijhpm.2018.84
      https://www.ijhpm.com/article_3540.html
      https://iranjournals.nlai.ir/handle/123456789/82129

      مرور

      همه جای سامانهپایگاه‌ها و مجموعه‌ها بر اساس تاریخ انتشارپدیدآورانعناوینموضوع‌‌هااین مجموعه بر اساس تاریخ انتشارپدیدآورانعناوینموضوع‌‌ها

      حساب من

      ورود به سامانهثبت نام

      تازه ترین ها

      تازه ترین مدارک
      © کليه حقوق اين سامانه برای سازمان اسناد و کتابخانه ملی ایران محفوظ است
      تماس با ما | ارسال بازخورد
      قدرت یافته توسطسیناوب